GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Association for Cancer Research (AACR)  (16)
Material
Publisher
  • American Association for Cancer Research (AACR)  (16)
Person/Organisation
Language
Years
Subjects(RVK)
  • 1
    Online Resource
    Online Resource
    Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19
    American Association for Cancer Research (AACR) ; 2022
    In:  Blood Cancer Discovery Vol. 3, No. 3 ( 2022-05-05), p. 181-193
    Details
    In: Blood Cancer Discovery, American Association for Cancer Research (AACR), Vol. 3, No. 3 ( 2022-05-05), p. 181-193
    Abstract: Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe COVID-19 is increased by anticancer therapy, is uncertain. Using data derived from the COVID-19 and Cancer Consortium (CCC19), we show that patients treated for B-lymphoid malignancies have an increased risk of severe COVID-19 compared with control populations of patients with non–B-lymphoid malignancies. Among patients with B-lymphoid malignancies, those who received anticancer therapy within 12 months of COVID-19 diagnosis experienced increased COVID-19 severity compared with patients with non–recently treated B-lymphoid malignancies, after adjustment for cancer status and several other prognostic factors. Our findings suggest that patients recently treated for a B-lymphoid malignancy are at uniquely high risk for severe COVID-19. Significance: Our study suggests that recent therapy for a B-lymphoid malignancy is an independent risk factor for COVID-19 severity. These findings provide rationale to develop mitigation strategies targeted at the uniquely high-risk population of patients with recently treated B-lymphoid malignancies. This article is highlighted in the In This Issue feature, p. 171
    Type of Medium: Online Resource
    ISSN: 2643-3230 , 2643-3249
    URL: Article
    DOI: 10.1158/2643-3230.BCD-22-0013
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2022
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Abstract PO-076: Strategies to improve the reach of interventions to address inequities in cancer care: Results from a six-site initiative
    American Association for Cancer Research (AACR) ; 2020
    In:  Cancer Epidemiology, Biomarkers & Prevention Vol. 29, No. 12_Supplement ( 2020-12-01), p. PO-076-PO-076
    Details
    In: Cancer Epidemiology, Biomarkers & Prevention, American Association for Cancer Research (AACR), Vol. 29, No. 12_Supplement ( 2020-12-01), p. PO-076-PO-076
    Abstract: Introduction: Large segments of the United States population do not receive quality cancer care due to pervasive and systemic inequities. Disparate cancer care is associated with increased morbidity and mortality. Multi-component, multi-level interventions can address inequities and improve care, but only if they reach populations of interest. Intervention studies often under-enroll populations of interest, despite having an adequate eligible pool. Procedures: The Alliance to Advance Patient-Centered Cancer Care supports six grantees across the US to implement diverse multi-component (e.g., access, symptom monitoring, wellness, survivorship), multi-level (e.g., patients, clinicians, caregivers) intervention programs with the shared goals of reducing disparities, increasing patient engagement, and improving the quality of cancer care. The Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework informs the evaluation efforts across the six sites. An important first step is to reach and enroll individuals who are most in need of cancer screening or access to cancer treatment. Target populations across sites include underrepresented minorities (e.g., Black and Latinx persons), those who speak English as a second language, and rural residents. Each participating site defined the target population(s) for their program. The sites used four key strategies to reach their target populations, which included: lay and clinical navigators, community advisory boards, data algorithms to conduct eligibility screening from the electronic health record, and dynamic community-based participatory research approaches. For years 2018-2019, we evaluated the demographic characteristics of participants recruited to program interventions compared to the overall demographic characteristics of each site’s pool of potentially eligible participants. Summary data: Of 4,692 potentially eligible participants, the six sites have enrolled 1,880 participants to date. Below we report the proportion of individuals with selected characteristics from the total enrolled: Black adults: 39% enrolled, (n=733), Latinx adults: 23% enrolled, (n=432), English as second language speakers: 19% enrolled, (n=357), and rural residents: 25% enrolled, (n=470). These proportions were similar or exceeded the proportions observed across the entire pool of eligible persons. Specifically, of 4,692 eligible persons across all sites, 35% were Black adults, 19% were Latinx adults, 15% spoke English as a second language, and 23% resided in rural areas. Conclusion: The Alliance to Advance Patient-Centered Cancer Care grantees have met or exceeded target enrollments from underserved groups to patient-centered intervention programs. Intentional strategies that include human resources, technology, and community engagement are needed and can be successful in improving access to high-quality cancer screening, treatment, and supportive care. Citation Format: Debra L. Barton, Bidisha Ghosh, Heidi A. Hamann, Sanja Percac-Lima, Adrian S. Dobs, Michelle J. Naughton, Roland P. Matthews, Sheryl Gabram-Mendola, Melissa A. Simon, Yvonne Bueno, Beverly Moy, Electra D. Paskett, Sankirtana M. Danner, Bingxin Chen, Robert J. Ploutz- Snyder, Christopher R. Friese. Strategies to improve the reach of interventions to address inequities in cancer care: Results from a six-site initiative [abstract]. In: Proceedings of the AACR Virtual Conference: Thirteenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2020 Oct 2-4. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2020;29(12 Suppl):Abstract nr PO-076.
    Type of Medium: Online Resource
    ISSN: 1055-9965 , 1538-7755
    URL: Article
    DOI: 10.1158/1538-7755.DISP20-PO-076
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2020
    detail.hit.zdb_id: 2036781-8
    detail.hit.zdb_id: 1153420-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Adjuvant chemotherapy for breast cancer – prognostic impact of relative dose-intensity.
    American Association for Cancer Research (AACR) ; 2009
    In:  Cancer Research Vol. 69, No. 2_Supplement ( 2009-01-15), p. 4109-
    Details
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 69, No. 2_Supplement ( 2009-01-15), p. 4109-
    Abstract: Abstract #4109 Introduction: Maintenance of adequate dose intensity (DI) is an important aim in the use of adjuvant chemotherapy for early breast cancer. Some studies report a decreased survival, if the DI is below 80% of the planned dose. We evaluated the rate of decreased DI and its prognostic impact for patients (pts.) treated in our institution between 1990 and 2004. During the long observation period a variety of regimens were used: CMF, normal dosed anthracycline (norA) based regimens (Epirubicin less than 35 mg/sqm*week) and higher dosed anthracyclines (hiA; Epirubicin doses of more than 45 mg/sqm*week). & #x2028; Methods: All patient files were reviewed to calculate relative DI; cycles not applied were treated as a 100% dose reduction. Follow up-data were taken from our institutional prospective data base and the regional tumor registry. Excluded from the analysis were pts. with high dose chemotherapy with stem cell support, rare regimens (less than 10 cases / regimen), pts. switching institution during therapy and pts. progressing during chemotherapy. & #x2028; Results: From 966 pts. receiving adjuvant chemotherapy, 887 matched the inclusion criteria. Mean follow up is 70 months with 260 distant progressions and 234 deaths. 193 pts. received CMF, 442 norA and 252 hiA, 302 pts. received taxanes. Preterm termination of chemotherapy occurred in 77 pts (8.7%), dose reductions in 36 pts. (4.1%). Pts. receiving hiA were at higher risk for dose reductions than with norA and CMF (7.5% vs. 2.9% vs. 2.1%, p=0.015). Mean dose delays were 12.7 days (CMF), 6.4 days (norA) and 5.7 (hiA) (p & lt;0.01, Kruskal-Wallis-test). The mean rel. DI were 90% (CMF), 93% (norA) and 92% (hiA) and significantly different (p=0.01, Kruskal-Wallis-test). & #x2028; In univariate analysis, 5 year-metastasis free survival (MFS, 74% vs. 55%, p=0.002) and overall survival (OAS, 80% vs. 65%, p=0.009) are significantly lower for pts. with a rel. DI of less than 80%. This effect seems more pronounced for norA (OAS 80% vs. 45%), than for CMF (OAS 74% vs. 74%) and hiA (OAS 85% vs. 77%). The adverse effect of low DI was independent of taxan-use. In a cox-regression analysis low DI was not identified as independent predictor for MFS and OAS. & #x2028; Conclusions: Compared to DI reported from most prospective randomised trials the DI in this study seems lower, potentially reflecting patient selection. Dose reductions, delays and preterm termination are common findings, leading to impaired DI. In our study low DI is associated with adverse prognosis in univariate, but not in multivariate analysis. Nevertheless, unnecessary dose modifications should be avoided. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 4109.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    URL: Article
    DOI: 10.1158/0008-5472.SABCS-4109
    RVK:
    XA 36000
    RVK:
    XA 10000
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2009
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    PD07-01: Sequential Treatment with Epirubicin/Cyclophosphamide, Followed by Docetaxel vs. FEC120 in the Adjuvant Treatment of Breast Cancer Patients with Extensive Lymph Node Involvement: Final Survival Analysis of the German ADEBAR Phase III Study.
    American Association for Cancer Research (AACR) ; 2011
    In:  Cancer Research Vol. 71, No. 24_Supplement ( 2011-12-15), p. PD07-01-PD07-01
    Details
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 71, No. 24_Supplement ( 2011-12-15), p. PD07-01-PD07-01
    Abstract: Background: Based on meta-analytic evidence, taxane containing adjuvant chemotherapy has been established as standard treatment in node-positive breast cancer. However, in the MA-21 study, adriamycin-cyclophosphamide, followed by paclitaxel (AC-P) was significantly inferior to the gold standard of anthracycline treatment, FEC120 (Burnell, SABCS 2006). We prospectively compared a sequential epirubicin-docetaxel chemotherapy regimen to FEC120. Patients and Methods: The ADEBAR study was a multicenter phase III trial (n=1502) to evaluate whether breast cancer (BC) pts with & gt; 3 axillary lymph node metastases benefit from a sequential anthracycline-docetaxel regimen (E90C-D: 4 cycles epirubicin [E] 90 mg/m2 plus cyclophosphamide [C] 600 mg/m2 q21 days followed by 4 cycles docetaxel [D] 100mg/m2 q21 days) compared to dose-intensive anthracycline-containing polychemotherapy (FE120C: 6 cycles E 60 mg/m2 d 1+8, 5-FU 500mg/m2 d 1+8 and C 75 mg/m2 d 1–14, q4 weeks). The median follow-up time will be 60 months. Results: Treatment was stopped prematurely in 3.7% of the pts in the E90C-D arm and in 8.0% in the FE120C arm due to toxicity (p=0.0009). Antibiotic treatment was given in 10.4% (E90C-D) vs. 19.7% (FE120C), G-CSF support in 39.2% vs 61.4% and erythropoietin stimulation in 8.7% vs. 20.0%, respectively (p & lt;0.0001). Haematological toxicity (leucopenia, neutropenic fever, thrombocytopenia, anemia) was significantly higher in the FE120C-arm. Mature final 5-year-survival data will be presented at the SABCS meeting 2011. Conclusion: Different toxicity profiles given, hematological toxicity in the FE120C group was more severe than in the E90C-D. Mature survival data will be discussed in this context. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr PD07-01.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    URL: Article
    DOI: 10.1158/0008-5472.SABCS11-PD07-01
    RVK:
    XA 36000
    RVK:
    XA 10000
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2011
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study
    American Association for Cancer Research (AACR) ; 2020
    In:  Cancer Discovery Vol. 10, No. 10 ( 2020-10-01), p. 1514-1527
    Details
    In: Cancer Discovery, American Association for Cancer Research (AACR), Vol. 10, No. 10 ( 2020-10-01), p. 1514-1527
    Abstract: Among 2,186 U.S. adults with invasive cancer and laboratory-confirmed SARS-CoV-2 infection, we examined the association of COVID-19 treatments with 30-day all-cause mortality and factors associated with treatment. Logistic regression with multiple adjustments (e.g., comorbidities, cancer status, baseline COVID-19 severity) was performed. Hydroxychloroquine with any other drug was associated with increased mortality versus treatment with any COVID-19 treatment other than hydroxychloroquine or untreated controls; this association was not present with hydroxychloroquine alone. Remdesivir had numerically reduced mortality versus untreated controls that did not reach statistical significance. Baseline COVID-19 severity was strongly associated with receipt of any treatment. Black patients were approximately half as likely to receive remdesivir as white patients. Although observational studies can be limited by potential unmeasured confounding, our findings add to the emerging understanding of patterns of care for patients with cancer and COVID-19 and support evaluation of emerging treatments through inclusive prospective controlled trials. Significance: Evaluating the potential role of COVID-19 treatments in patients with cancer in a large observational study, there was no statistically significant 30-day all-cause mortality benefit with hydroxychloroquine or high-dose corticosteroids alone or in combination; remdesivir showed potential benefit. Treatment receipt reflects clinical decision-making and suggests disparities in medication access. This article is highlighted in the In This Issue feature, p. 1426
    Type of Medium: Online Resource
    ISSN: 2159-8274 , 2159-8290
    URL: Article
    DOI: 10.1158/2159-8290.CD-20-0941
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2020
    detail.hit.zdb_id: 2607892-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    P4-07-06: Correlation of Two Analytical Methods for Circulating Tumor Cells in Peripheral Blood of Patients with Primary Breast Cancer.
    American Association for Cancer Research (AACR) ; 2011
    In:  Cancer Research Vol. 71, No. 24_Supplement ( 2011-12-15), p. P4-07-06-P4-07-06
    Details
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 71, No. 24_Supplement ( 2011-12-15), p. P4-07-06-P4-07-06
    Abstract: Background While the evidence for circulating tumor cells (CTCs) as a prognostic marker in metastatic breast cancer has been well established, there is still a lack of data in primary disease. In the SUCCESS A trial two different techniques for the detection of CTCs in early breast cancer were prospectively evaluated. Material and Methods: SUCCESS A compared FEC-Docetaxel vs. FEC-Docetaxel-Gemcitabine and 5 vs. 2 years of treatment with zoledronic acid in primary breast cancer patients and node positive or high-risk node negative disease. Two different techniques to detect CTCs were prospectively evaluated in two consecutive, but comparable subgroups of the whole study population. In 3515 samples the CellSearch® System (Veridex, Warren, USA) was used for CTC detection. Immunomagnetic enrichment with an EPCAM-antibody was followed by labeling with monoclonal antibodies specific for cytokeratin (8, 18, 19) and leukocytes (CD45). 2165 samples were evaluated with a manual immunocytochemistry (MICC) protocol. Cytospins were prepared after mononuclear cell enrichment based on Oncoquick® centrifugation (greiner bio-one, Frickenhausen, Germany). Staining was performed with the monoclonal pancytokeratin antibody A45-B/B3 (Micromet, Munich, Germany) and the APAAP technique. Conventional light field microscopy (Axiophot; Zeiss, Oberkochen, Germany) was used for the detection of stained cells. For both methods, the cut-off value for positivity was ≥ 1 CTC. All events were evaluated by two independent observers. Results: CTCs were examined in a total number of 3243 patients before and after chemotherapy (CHT). The two subgroups evaluated with one or the other method were well-balanced regarding clinical parameters as tumor size, grading, lymph node-status, hormone receptors and Her2. Furthermore there was no significant correlation between the CTC positivity and one of these clinical parameters using CellSearch or the MICC, respectively (p & gt; 0,05 using the chi square test each time). Before adjuvant CHT 21. 3% (424 out of 1994) and 21.1 % (264 out of 1249) of the patients were found positive for CTCs using CellSearch® or the MICC respectively, with a mean CTC level of 5.9 (range: 1 to 827) and 3.1 (range: 1 to 256). Immediately after CHT 21.9% (333 out of 1521) and 16.5% (151 out of 916) of the patients were positive for CTCs using CellSearch® or the MICC. The mean CTC level decreased to 3.0 (range: 1 to 124) and 2.1 (range: 1 to 23) in both analytical methods. Using CellSearch® there was a significant correlation between the presence of CTCs before CHT and disease progression (p = 0.0044), as well as survival (p = 0.0001), whereas the MICC did not predict any of these (p = 0.3143 and p = 0.0801 respectively; the chi-square test was used each time). Conclusion: We found comparable prevalence of CTCs before and after adjuvant chemotherapy both with the CellSearch® System or the MICC. However, prognostic relevance could only be shown for CTCs detected with the CellSearch® System. This may be attributed to the high standardization and reproducibility of the automated system, as well as the additional CD45 counterstaining. According to our findings, the FDA approved CellSearch® System should be used as gold standard for CTC detection in future clinical trials. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-07-06.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    URL: Article
    DOI: 10.1158/0008-5472.SABCS11-P4-07-06
    RVK:
    XA 36000
    RVK:
    XA 10000
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2011
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    Prognostic relevance of circulating tumor cells (CTCs) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy – translational research program of the German SUCCESS-trial.
    American Association for Cancer Research (AACR) ; 2009
    In:  Cancer Research Vol. 69, No. 2_Supplement ( 2009-01-15), p. 303-
    Details
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 69, No. 2_Supplement ( 2009-01-15), p. 303-
    Abstract: Abstract #303 Background: & #x2028; The detection of Disseminated Tumor Cells in the Bone Marrow (BM) of Breast Cancer patients has shown prognostic significance in all stages of the disease. An alternative towards BM examination could be the analysis of peripheral blood for Circulating Tumor Cells (CTCs), which has demonstrated prognostic significance in metastatic disease. We analyzed peripheral blood samples from pts. Before and after adjuvant taxane-based chemotherapy as part of the translational research program of the German SUCCESS-trial. & #x2028; Methods: Peripheral blood samples (23 ml each) from 1500 N+ and high risk N- breast cancer pts were analyzed for the presence of CTCs with the CellSearchSystem (Veridex, USA) before and after adjuvant chemotherapy. After automated immunomagnetic enrichment with an anti-Epcam-antibody, cells are labelled with anti-cytokeratin (8,18,19) and anti-CD45 antibodies to distinguish between epithelial cells and leukocytes. Samples are screened automatedly and positive events are visualised on a screen for re-evaluation. & #x2028; Results: In143 pts (10 %) more than 1 CTC was detected before the start of systemic treatment (mean 14, range 2-827). 2 CTCs were found in 4 % of pts, 3 % had 3-5 CTCs and 1 % 6-10 and & gt;10 CTCs, resp. The presence of CTCs did not correlate with tumor size (p=.32), grading (p=.36), hormonal status (p=.28) or Her2 status of the primary tumor (p=.82), but with the presence of lymph node metastases (p=.003). As negative control, three of 74 healthy individuals showed more than 1 CTC. & #x2028; After completion of chemotherapy, 9 % of pts (n=130) presented with & gt;1 CTC (mean 6, range 2-124). Of those initially CTC positive, 10% remained positive (n=15), whereas of those initially CTC negative, 8 % turned positive after chemotherapy (n=115, p=.42). & #x2028; 21 recurrences have been reported during a median follow-up time of 12 months, and 7 pts have died of their disease. While detection of CTCs before systemic treatment did not show prognostic relevance for DFS (p=.89) and OAS (p=.71), presence of CTCs after chemotherapy was a significant predictor for both reduced DFS (p=.04) and OAS (p=.03). & #x2028; Conclusions: & #x2028; Our preliminary results demonstrate prognostic relevance of the presence of CTCs after adjuvant chemotherapy for the first time. Even in the adjuvant setting as well as during follow up, the examination of CTCs could be a valuable tool for monitoring the disease and the effectiveness of therapies. Longer follow-up of the SUCCESS-trial will have to be awaited to confirm these findings. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 303.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    URL: Article
    DOI: 10.1158/0008-5472.SABCS-303
    RVK:
    XA 36000
    RVK:
    XA 10000
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2009
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    Sequential Treatment with Epirubicin/Cyclophosphamide, Followed by Docetaxel Is Equieffective, but Less Toxic Than FEC120 in the Adjuvant Treatment of Breast Cancer Patients with Extensive Lymph Node Involvement: The German ADEBAR Phase III Study.
    American Association for Cancer Research (AACR) ; 2009
    In:  Cancer Research Vol. 69, No. 24_Supplement ( 2009-12-15), p. 604-604
    Details
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 69, No. 24_Supplement ( 2009-12-15), p. 604-604
    Abstract: Background: Based on meta-analytic evidence, taxane containing adjuvant chemotherapy has been established as standard treatment in node-positive breast cancer. However, in the MA-21 study, adriamycin-cyclophosphamide, followed by paclitaxel (AC-P) was significantly inferior to the gold standard of anthracycline treatment, FEC120 (Burnell, SABCS 2006). We prospectively compared a sequential epirubicin-docetaxel chemotherapy regimen to FEC120.Patients and Methods:The ADEBAR study was a multicenter phase III trial (n=1502) to evaluate whether breast cancer (BC) pts with & gt; 3 axillary lymph node metastases benefit from a sequential anthracycline-docetaxel regimen (E90C–D: 4 cycles epirubicin [E] 90 mg/m2 plus cyclophosphamide [C] 600 mg/m2 q21 days followed by 4 cycles docetaxel [D] 100mg/m2 q21 days) compared to dose-intensive anthracycline-containing polychemotherapy (FE120C: 6 cycles E 60 mg/m² d 1+8, 5-FU 500mg/m² d 1+8 and C 75 mg/m² d 1-14, q4 weeks). The median follow-up time was 47 mts.(range 2-83 mts).Results:Treatment was stopped prematurely in 3.7% of the pts in the E90C–D arm and in 8.0% in the FE120C arm due to toxicity (p=0.0009). Antibiotic treatment was given in 10.4% (E90C–D) vs. 19.7% (FE120C), G-CSF support in 39.2% vs 61.4 % and erythropoietin stimulation in 8.7% vs. 20.0%, respectively (p & lt;0.0001). Haematological toxicity (leucopenia, neutropenic fever, thrombocytopenia, anemia) was significantly higher in the FE120C-arm.At the time of the current analysis, 281 events of recurrence of breast cancer, were observed: 128 events in the FE120C group and 153 in the E90C–D group. The unadjusted hazard ratio (HR) was 0.88 (95 percent confidence interval, 0.694 to 1.115; p=0.2197, log-rank test). Overall survival in the two groups was not significantly different: (84 deaths with FE120C vs. 88 with E90C–D (HR 0.999, 0.738-1.352, p=0.99). Subgroup analyses, stratifying for tumor size, lymph node involvement, hormone receptor and HER2-neu status showed no significant difference between the two treatment arms.Conclusion:Different toxicity profiles given, hematological toxicity in the FE120C group was more severe than in the E90C–D.In contrast to AC-P in earlier studies, EC-Doc provides a feasible and effective alternative option to dose-intensified FEC with different saftey profile in this high risk breast cancer cohort. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 604.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    URL: Article
    DOI: 10.1158/0008-5472.SABCS-09-604
    RVK:
    XA 36000
    RVK:
    XA 10000
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2009
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 9
    Online Resource
    Online Resource
    P4-02-07: Influence of the Progesterone Receptor on the Prognosis of Breast Cancer in Interaction with Other Prognostic Factors.
    American Association for Cancer Research (AACR) ; 2011
    In:  Cancer Research Vol. 71, No. 24_Supplement ( 2011-12-15), p. P4-02-07-P4-02-07
    Details
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 71, No. 24_Supplement ( 2011-12-15), p. P4-02-07-P4-02-07
    Abstract: Introduction: The expression of the estrogen receptor (ER) and/or the progesterone receptor (PR) is a predictive factor for the response to endocrine treatment and to chemotherapy in primary breast cancer. Knowledge about the prognostic relevance of the PR is rare and partly controversial. Aim of this retrospective study was to analyze the prognostic relevance of PR. Methods: Between 1995 and 2008, data from 5,144 patients with heterogeneously treated primary breast cancers have been collected in 3 German university hospitals. The laboratories used immunhistochemical assays for the investigation of the ER and PR. The PR-expression was correlated with patient and tumor characteristics. For each outcome parameter overall survival (OS), distant disease free survival (DDFS) and local recurrence free survival (LRFS) cox proportional hazad models were built. Furthermore the effect of the PR status was analyzed according to tumor subgroups. Results: PR status was associated with a more favourable OS, DDFS and LRFS in the univariate analysis. PR remained an independent prognostic factor for OS and DDFS but not for LRFS in the cox proportional hazard model. For OS and DDFS the prognostic effect of PR seemed to be consistent among the subgroups and was significant for most of them. Comparing subgroups there was a difference between the HR for ER negatives and ER positives. In ER negative tumors the prognostic effect of the PR seemed to be larger (HR=0.40; 95%CI: 0.25−0.63) than in ER positives (HR=0.68; 95%CI: 0.53−0.87). For all other subgroups there seemed to be no interaction between PR status and the other prognostic factors. Conclusion: PR positivity results into a similarly favourable prognosis in ER negative and ER positive patients. ER positivity alone seems not to be sufficient to define a group of patients with the most favourable prognosis. On the contrary, patients with ER positive, PR negative tumors have a signicantly deteriorated prognosis and seem to be a patient group, which should be investigated concerning drug resistance mechanisms. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-02-07.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    URL: Article
    DOI: 10.1158/0008-5472.SABCS11-P4-02-07
    RVK:
    XA 36000
    RVK:
    XA 10000
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2011
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 10
    Online Resource
    Online Resource
    Inhibin A Is Downregulated during Chemotherapy in Patients with Early Breast Cancer.
    American Association for Cancer Research (AACR) ; 2009
    In:  Cancer Research Vol. 69, No. 24_Supplement ( 2009-12-15), p. 3028-3028
    Details
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 69, No. 24_Supplement ( 2009-12-15), p. 3028-3028
    Abstract: Introduction: Inhibins are dimeric glycoproteins, composed of an alpha-subunit (INH-a) and one of two possible beta-subunits (ßA or ßB), with substantial roles in human reproduction and in endocrine-responsive tumours. In breast cancer tissue, the growth factor Inhibin A is involved in cell differentiation and proliferation, thus suggesting a possible role as tumor marker. Aims of this study were to determine the serological measurement of Inhibin A (a- bA) in breast cancer patients during chemotherapy.Material and Methods: A series of 28 high risk N0 and N+ breast cancer patients who underwent standardized chemotherapy (3 x FEC and 3 x Docetaxel) followed by two years of zoledronate in the German SUCCESS trial were prospectively evaluated before chemotherapeutic treatment as well as after chemotherapy and two years after chemotherapy for the serological expression of Inhibin A. For serological analysis the ultrasensitive Inhibin A ELISA (DSL – U.S.A.) was used according to manufactures instruction. For statistical analysis the Wilcoxon rang sum test was used for paired samples. Statistical significance was assumed at p & lt; 0.05.Results: The concentration of Inhibin A showed a significant decrease between data obtained before chemotherapy and after chemotherapy (p & lt;0.005) and two-year follow up (p & lt;0.001). Interestingly, there were seen no differences between the time point four weeks after chemoherapy and at two years (p=0.744).Discussion: Therefore, chemotherapy decreases significantly the Inhibin A concentration during chemotherapy. This might reflect a suppression of ovarian function and might be a marker for chemotherapy-induced amenorrhoea. Moreover, it has been suggested that Inhibin A might be a tumour marker for breast cancer, and therefore a sudden increase of its concentration might be indicative of breast cancer recurrence. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3028.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    URL: Article
    DOI: 10.1158/0008-5472.SABCS-09-3028
    RVK:
    XA 36000
    RVK:
    XA 10000
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2009
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...